Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATYPUS: Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies
NCT05179876Phase 3Recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of macitentan, selexipag, tadalafil in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started May 2022; status: recruiting.
02
Drugs
macitentanselexipagtadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05179876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179876.